Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck On Track to File Application for Insomnia Drug This Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 02:52pm CEST
   By Victoria Stilwell 
 

Merck & Co. (MRK) said it is on track to file a new drug application for its experimental insomnia medicine this year, making the drug one of six major filings planned for 2012 and 2013.

Data from a Phase 3 clinical trial showed Merck's insomnia drug suvorexant reduced the time it took patients to fall asleep and increased the time patients stayed asleep as early as the first night and at the three-month point compared with a placebo.

The drug met statistical significance on 15 out of 16 primary endpoints. The findings were to be presented at the Annual Meeting of the Associated Professional Sleep Societies.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

Merck reported in April first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed at $38.43 Tuesday and were inactive in premarket trade. The stock is up 8.8% in the past 12 months.

Write to Victoria Stilwell at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
10:40a ADAPTIMMUNE THERAPEUTICS : Announces Initiation of Study to Evaluate SPEAR T-Cel..
05/26 TEIJIN : Pharma to Enter into Worldwide License Agreement with Merck & Co., Inc...
05/26 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
05/25 MERCK : Studies from Merck & Company Reveal New Findings on Pharmaceutical Scien..
05/25 OPTUM : and Merck Collaborate to Advance Value-Based Contracting of Pharmaceutic..
05/25 MERCK & CO., INC. (NYSE : MRK) Files An 8-K Submission of Matters to a Vote of S..
05/25 MERCK & CO., INC. : Submission of Matters to a Vote of Security Holders (form 8-..
05/25 MERCK : Enters Exclusive Worldwide License Agreement with Teijin Pharma for Inve..
05/23 MERCK : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pedia..
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05:09a 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 27, 2017
05/26 Time For Tau - For Now
05/26 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 26, 2017
05/25 Is OncoMed A Contrarian Buy?
05/25 FDA drug approvals rebound from last year, up over 100% yoy
Advertisement
Financials ($)
Sales 2017 39 953 M
EBIT 2017 13 660 M
Net income 2017 7 128 M
Debt 2017 2 429 M
Yield 2017 2,89%
P/E ratio 2017 24,99
P/E ratio 2018 18,93
EV / Sales 2017 4,51x
EV / Sales 2018 4,37x
Capitalization 177 567 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,3 $
Spread / Average Target 6,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.10.28%177 567
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.88%236 581
NOVARTIS AG6.75%211 457
PFIZER INC.-1.05%191 398
SANOFI13.54%123 549
More Results